EP1121118A4 - Formamide als therapeutische mittel - Google Patents

Formamide als therapeutische mittel

Info

Publication number
EP1121118A4
EP1121118A4 EP99942456A EP99942456A EP1121118A4 EP 1121118 A4 EP1121118 A4 EP 1121118A4 EP 99942456 A EP99942456 A EP 99942456A EP 99942456 A EP99942456 A EP 99942456A EP 1121118 A4 EP1121118 A4 EP 1121118A4
Authority
EP
European Patent Office
Prior art keywords
formamides
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99942456A
Other languages
English (en)
French (fr)
Other versions
EP1121118A1 (de
Inventor
Robert Carl Andrews
Marc Werner Andersen
David John Cowan
David Norman Deaton
Scott Howard Dickerson
David Harold Drewry
Michael David Gaul
Michael Joseph Luzzio
Brian Edward Marron
Michael Howard Rabinowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818613.3A external-priority patent/GB9818613D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1121118A1 publication Critical patent/EP1121118A1/de
Publication of EP1121118A4 publication Critical patent/EP1121118A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
EP99942456A 1998-08-26 1999-08-25 Formamide als therapeutische mittel Withdrawn EP1121118A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9795698P 1998-08-26 1998-08-26
GBGB9818613.3A GB9818613D0 (en) 1998-08-26 1998-08-26 Formamides as therapeutic agents
GB9818613 1998-08-26
US97956P 1998-08-26
PCT/US1999/019303 WO2000012083A1 (en) 1998-08-26 1999-08-25 Formamides as therapeutic agents

Publications (2)

Publication Number Publication Date
EP1121118A1 EP1121118A1 (de) 2001-08-08
EP1121118A4 true EP1121118A4 (de) 2002-09-11

Family

ID=26314265

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99942456A Withdrawn EP1121118A4 (de) 1998-08-26 1999-08-25 Formamide als therapeutische mittel

Country Status (4)

Country Link
EP (1) EP1121118A4 (de)
JP (1) JP2002523454A (de)
AU (1) AU5582899A (de)
WO (1) WO2000012083A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202012671D0 (en) 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0236872A2 (de) * 1986-03-11 1987-09-16 F. Hoffmann-La Roche Ag Hydroxylaminderivate, deren Herstellung und Verwendung für Heilmittel
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
WO1994010990A1 (en) * 1992-11-13 1994-05-26 British Biotech Pharmaceuticals Limited Inhibition of tnf production
WO1995032944A1 (en) * 1994-05-28 1995-12-07 British Biotech Pharmaceuticals Limited Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
WO1997003783A1 (en) * 1995-07-20 1997-02-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1997019053A1 (en) * 1995-11-23 1997-05-29 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1998038179A1 (en) * 1997-02-26 1998-09-03 Glaxo Group Limited Reverse hydroxamate derivatives as metalloprotease inhibitors
WO2000012082A1 (en) * 1998-08-26 2000-03-09 Glaxo Group Limited Formamide compounds as therapeutic agents
GB2348198A (en) * 1998-08-26 2000-09-27 Glaxo Group Ltd Formamide derivatives as metalloprotease inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0236872A2 (de) * 1986-03-11 1987-09-16 F. Hoffmann-La Roche Ag Hydroxylaminderivate, deren Herstellung und Verwendung für Heilmittel
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
WO1994010990A1 (en) * 1992-11-13 1994-05-26 British Biotech Pharmaceuticals Limited Inhibition of tnf production
WO1995032944A1 (en) * 1994-05-28 1995-12-07 British Biotech Pharmaceuticals Limited Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
WO1997003783A1 (en) * 1995-07-20 1997-02-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1997019053A1 (en) * 1995-11-23 1997-05-29 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1998038179A1 (en) * 1997-02-26 1998-09-03 Glaxo Group Limited Reverse hydroxamate derivatives as metalloprotease inhibitors
WO2000012082A1 (en) * 1998-08-26 2000-03-09 Glaxo Group Limited Formamide compounds as therapeutic agents
GB2348198A (en) * 1998-08-26 2000-09-27 Glaxo Group Ltd Formamide derivatives as metalloprotease inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOURNIÉ-ZALUSKI; COULAUD AND CO.: "New Bidentates as Full Inhibitors of Enkephalin-Degrading Enzymes: Synthesis and Analgesic Properties", J. MED. CHEM., vol. 28, 1985, pages 1158 - 1169, XP002202645 *
See also references of WO0012083A1 *

Also Published As

Publication number Publication date
AU5582899A (en) 2000-03-21
JP2002523454A (ja) 2002-07-30
EP1121118A1 (de) 2001-08-08
WO2000012083A1 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
GB9820113D0 (en) Therapeutic agents
GB9816263D0 (en) Therapeutic agents
GB9806102D0 (en) Therapeutic agents
GB9808663D0 (en) Therapeutic agents
GB9801234D0 (en) Therapeutic agents
GB9813576D0 (en) Therapeutic agents
GB9813006D0 (en) Therapeutic agents
GB9801210D0 (en) Therapeutic agents
AP9901436A0 (en) Therapeutic agents
GB9801397D0 (en) Therapeutic agents
GB9801202D0 (en) Therapeutic agents
GB9810092D0 (en) Therapeutic agents
GB9819484D0 (en) Therapeutic agents
GB9811879D0 (en) Therapeutic agents
GB9815317D0 (en) Therapeutic agents
GB9810920D0 (en) Therapeutic use
GB9812662D0 (en) Therapeutic use
EP1121118A4 (de) Formamide als therapeutische mittel
GB9805716D0 (en) Therapeutic agents
GB9817838D0 (en) Therapeutic agents
GB9818613D0 (en) Formamides as therapeutic agents
GB9816723D0 (en) Therapeutic agents
GB9811624D0 (en) Therapeutic use
GB9812664D0 (en) Therapeutic use
GB9821517D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020731

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030409